New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compare
Tweet Content
New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated.
Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA
IH https://t.co/RvcONHCLvz
Show on Archive Page
On
Display in Search Results
On
PDQ
Off